Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

44132 reported adverse events

Drugs of this class: EFAVIRENZ NEVIRAPINE EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE ETRAVIRINE EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE DORAVIRINE DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

# Side effect Count
0 BONE DENSITY DECREASED 8652
1 CHRONIC KIDNEY DISEASE 5312
2 PAIN 4469
3 TOOTH LOSS 4365
4 RENAL INJURY 4351
5 RENAL FAILURE 4313
6 EMOTIONAL DISTRESS 4266
7 ANXIETY 4087
8 OSTEONECROSIS 3914
9 BONE LOSS 3913
See all common reactions for Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA 98 0.8909
1 HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION 145 0.6971
2 BONE DEMINERALISATION 256 0.5740
3 PINEALOBLASTOMA 49 0.5444
4 HIV-ASSOCIATED NEUROCOGNITIVE DISORDER 42 0.5185
5 TOOTH INJURY 1669 0.5154
6 CLOACAL EXSTROPHY 27 0.5000
7 BLADDER AGENESIS 32 0.4776
8 VIRAL MUTATION IDENTIFIED 1079 0.4397
9 VIROLOGIC FAILURE 1482 0.4226
See all enriched reactions for Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]